| Mikel Gray, NP | |
|
500 Ray C Hunt Dr Fl 3, Charlottesville, VA 22903-2981 | |
| (434) 924-2224 | |
| (434) 982-3652 |
| Full Name | Mikel Gray |
|---|---|
| Gender | Male |
| Speciality | Nurse Practitioner |
| Experience | 43 Years |
| Location | 500 Ray C Hunt Dr Fl 3, Charlottesville, Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073637708 | NPI | - | NPPES |
| 007781555 | Medicaid | VA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | 0024079837 (Virginia) | Secondary |
| 363L00000X | Nurse Practitioner | 0024079837 (Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Virginia Medical Center | Charlottesville, VA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Of Virginia Physicians Group | 4880590728 | 1397 |
News Archive
Using geriatric mice, a Johns Hopkins research team has shown that losartan, a commonly used blood pressure drug, not only improves regeneration of injured muscle but also protects against its wasting away from inactivity.
Vital Therapies, Inc., is pleased to announce that the first subject has been enrolled at National Guard Hospital in Riyadh, Kingdom of Saudi Arabia in the further expansion of its SILVER clinical trial to the Middle East. The trial is evaluating whether VTI's biological cellular therapy product, ELAD, can prevent deterioration of liver function and improve the survival of patients with acute-on-chronic liver failure.
Merz Pharmaceuticals announced today that data from stability and clinical studies evaluating Xeomin (incobotulinumtoxinA), a botulinum toxin type A free from accessory proteins, will be presented at the 71st Annual Assembly of the American Academy of Physical Medicine and Rehabilitation (AAPM&R) in Seattle, Wash.
At the annual conference of the DGKL, Bruker today announced the European launch of the novel, automated Toxtyper clinical mass spectrometry solution to meet the increasing demands for LC-MS/MS throughput and data quality in routine toxicology laboratories without the need for mass spectrometry expertise.
› Verified 3 days ago
| Entity Name | University Of Virginia Physicians Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033138250 PECOS PAC ID: 4880590728 Enrollment ID: O20040102000780 |
News Archive
Using geriatric mice, a Johns Hopkins research team has shown that losartan, a commonly used blood pressure drug, not only improves regeneration of injured muscle but also protects against its wasting away from inactivity.
Vital Therapies, Inc., is pleased to announce that the first subject has been enrolled at National Guard Hospital in Riyadh, Kingdom of Saudi Arabia in the further expansion of its SILVER clinical trial to the Middle East. The trial is evaluating whether VTI's biological cellular therapy product, ELAD, can prevent deterioration of liver function and improve the survival of patients with acute-on-chronic liver failure.
Merz Pharmaceuticals announced today that data from stability and clinical studies evaluating Xeomin (incobotulinumtoxinA), a botulinum toxin type A free from accessory proteins, will be presented at the 71st Annual Assembly of the American Academy of Physical Medicine and Rehabilitation (AAPM&R) in Seattle, Wash.
At the annual conference of the DGKL, Bruker today announced the European launch of the novel, automated Toxtyper clinical mass spectrometry solution to meet the increasing demands for LC-MS/MS throughput and data quality in routine toxicology laboratories without the need for mass spectrometry expertise.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mikel Gray, NP Po Box 9007, Charlottesville, VA 22906-9007 Ph: () - | Mikel Gray, NP 500 Ray C Hunt Dr Fl 3, Charlottesville, VA 22903-2981 Ph: (434) 924-2224 |
News Archive
Using geriatric mice, a Johns Hopkins research team has shown that losartan, a commonly used blood pressure drug, not only improves regeneration of injured muscle but also protects against its wasting away from inactivity.
Vital Therapies, Inc., is pleased to announce that the first subject has been enrolled at National Guard Hospital in Riyadh, Kingdom of Saudi Arabia in the further expansion of its SILVER clinical trial to the Middle East. The trial is evaluating whether VTI's biological cellular therapy product, ELAD, can prevent deterioration of liver function and improve the survival of patients with acute-on-chronic liver failure.
Merz Pharmaceuticals announced today that data from stability and clinical studies evaluating Xeomin (incobotulinumtoxinA), a botulinum toxin type A free from accessory proteins, will be presented at the 71st Annual Assembly of the American Academy of Physical Medicine and Rehabilitation (AAPM&R) in Seattle, Wash.
At the annual conference of the DGKL, Bruker today announced the European launch of the novel, automated Toxtyper clinical mass spectrometry solution to meet the increasing demands for LC-MS/MS throughput and data quality in routine toxicology laboratories without the need for mass spectrometry expertise.
› Verified 3 days ago